There are 2 resources available
627P - Phase II neoadjuvant trial of the anti–B7-H3 antibody, enoblituzumab, in men with localized prostate cancer: Safety, efficacy and immune correlates
Presenter: Eugene Shenderov
Session: ePoster Display
620P - MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors: Preliminary results of phase I cohort expansion
Presenter: Eugene Shenderov
Session: ePoster Display